{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HH8HGHNJ/b70143e1-957d-40fd-a8d0-5329e48766ef/PDF","dcterms:extent":"121 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HH8HGHNJ/0b0b101a-e4d9-44d5-ba41-08c96c84e411/TEXT","dcterms:extent":"46 KB"}],"edm:TimeSpan":{"@rdf:about":"1994-2025","edm:begin":{"@xml:lang":"en","#text":"1994"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-HH8HGHNJ","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-46R7GGHL"},{"@xml:lang":"sl","#text":"Medicinski razgledi"}],"dcterms:issued":"1997","dc:creator":["Goršič-Tomažič, Karmen","Marinko, Tanja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:36"},{"@xml:lang":"sl","#text":"str. 297-315"}],"dc:identifier":["ISSN:0025-8121","COBISSID:7908825","URN:URN:NBN:SI:doc-HH8HGHNJ"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Medicinski razgledi"},"dc:subject":[{"@xml:lang":"sl","#text":"bolniki"},{"@xml:lang":"en","#text":"Etiology"},{"@xml:lang":"sl","#text":"neodzivnost"},{"@xml:lang":"en","#text":"Partial thromboplastin time"},{"@xml:lang":"en","#text":"Physiology"},{"@xml:lang":"en","#text":"Protein c"},{"@xml:lang":"en","#text":"Thrombophlebitis"},{"@xml:lang":"sl","#text":"venska tromboza"},{"@rdf:resource":"http://www.wikidata.org/entity/Q521"}],"dcterms:temporal":{"@rdf:resource":"1994-2025"},"dc:title":{"@xml:lang":"sl","#text":"Pogostost neodzivnosti na aktivirani protein C pri bolnikih z vensko trombozo| Incidence of activated protein C resistance among patients with deep vein thrombosis|"},"dc:description":[{"@xml:lang":"sl","#text":"A group of 100 consecutive patients treated for deep vein thrombosis in the Trnovo Hospital of Intemal Medicine from January 1992 to December 1994, was studied for the presence of a new type of thrombophilia - resistance to activated protein C. There were 40 women and 60 men, aged 16 to 60 years (x=39). Primary deep vein thrombosis was established in 38 patients (18 % women, 82 % men), and secondary deep vein thrombosis in 62 patients (53 % women, 74 % men). Thirty-two per cent of patients had a positive family history; 79 per cent were treated for the first episode of deep vein thrombosis and the remainder for recurrent episodes. Resistance to activated protein C was determinated using a ratio between activated partial thromboplastin time with purified activated protein C and activated partial thro boplastin time without activated protein C. The lower normal limit was determined by measuring the activated protein C ratio in 100 sex and age matched healthy subjects (mean minus 2+- SD). Subjects with an activated protein C ratio less than 2,0 were considered resistant to activated protein C. Twenty patients were excluded from the study because of anticoagulant treatment, and 9 because of the presence of lupus anticoagulants. Activated protein C resistance was established in 10 (14 %) of the remaining 71 patients(6 women and 4 men). In the control group, the prevalence of activatedprotein C resistance was 3 per cent (3 men) (p < 0,05). One patient showed antithrombin III deficiency, and 2 patients protein C deficiency but none of them had activated protein C resistance. There were no association between activated protein C resistance and primary or secondary deep vein thrombosis, positive family history and first or recurrent episodes of the disease. The results of the study indicate that activated protein C resistanceis a frequent independent risk factor for deep vein thrombosis"},{"@xml:lang":"sl","#text":"Pri 100 zaporednih bolnikih, ki so se zaradi venske tromboze zdravili na Interni kliniki Trnovo v obdobju med januarjem 1992 in decembrom 1994, smo iskali novo obliko trombofilije - neodzivnost na aktivirani protein C. Med njimi je bilo 40 žensk in 60 moških, starih od 16 do 60 let (x=39). Zaradi primarne venske tromboze se je zdravilo 38 bolnikov (18 % žensk, 82 % moških).Sekundarno vensko trombozo je imelo 62 bolnikov, med njimi je bilo 53 % žensk in 47 % moških. Pri 32 % bolnikov se je pojavIjala venska tromboza v družini, 79 % bolnikov se je zdravilo zaradi prve, ostali pa zaradi ponovne venske tromboze. Za določanje neodzivnosti na aktivirani protein C smo izračunavali razmerje med aktiviranim parcialnim tromboplastinskim časom ob dodatku aktiviranega proteina C in brez njega. Spodnjo mejo normalne vred- nosti smo določili z meritvijo razmerja aktivira- nega proteina C pri 100 zdravih osebah, ki so po spolu in starosti ustrezale bolnikom z vensko trombozo (x+- SD). Osebe, ki so imele razmerje aktiviranega proteina C pod 2,0, smo označili kot neodzivne na aktivirani protein C. Pri določanju neodzivnosti na aktivirani protein C smo zaradi jemanja kumarinov izključili 20 bolnikov, zaradi prisotnosti lupusnih antikoagulantov pa 9 bolnikov. Med 71preostalimi bolniki smo odkrili neodzivnost na aktivirani protein C pri 10 (14%) bolnikih (6 žensk, 4 moški) za razliko od 3 (3 %) moških med kontrolnimiosebami (p < 0,05). Odkrili smo tudi 1 bolnika s pomanjkanjem antitrombina III in 2 bolnika s pomanjkanjem proteina C. Nihče od njih ni imelsočasne neodzivnosti na aktivirani protein C. Nismo odkrili povezave med neodzivnostjo na aktivirani protein C in primarno oz. sekundarno trombozo, družinskim pojavljanjem venske tromboze ter prvo oz. ponovno vensko trombozo. Rezultati naše raziskave kažejo, da je neodzivnost na aktivirani protein C pogost, samostojen dejavnik tveganja za nastanek venske tromboze"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-HH8HGHNJ","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-HH8HGHNJ"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-HH8HGHNJ/b70143e1-957d-40fd-a8d0-5329e48766ef/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Društvo Medicinski razgledi"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-HH8HGHNJ/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-HH8HGHNJ"}}}}